Japan’s Ministry of Health recently officially approved an antibody cocktail made up of a mixture of active ingredients “casirivimab” and “imdevimab”.
Japan’s Ministry of Health recently officially approved the use of antibody cocktails against SARS-CoV-2 domestically. Thus, after “Remdesivir”, “Steroid dexamethasone” and “Baricitinib”, the 4th drug approved in Japan against Covid-19 came into use.
The combination of antibodies consists of monoclonal antibodies called “casirivimab” and “imdevimab”, a type of protein designed to recognize and adhere to a particular structure. The Regeneron Pharmaceuticals-made cocktail was approved for emergency use in the United States in November 2020. It was emphasized that the drug could be used in patients who are in danger of progressing to a serious stage with conditions that do not require oxygen supplementation. The cocktail was used to treat US President Donald Trump, who contracted Covid-19 during his tenure.